🟢 Pacific Biosciences is trading 16% up today after EpiSign-Geneyx rare-disease partnership

Pacific Biosciences is trading 16.20% higher at $3.33 following news of an EpiSign and Geneyx partnership to bring PacBio HiFi sequencing data into rare-disease interpretation workflows.

• The workflows cover more than 300 disorders; coverage linked the partnership news to the prior session’s rise.
• On October 6, PacBio announced a TychoBio collaboration to generate RNA-sequencing data from more than 10,000 samples for RNA-therapy research. Reporting does not establish this collaboration as the direct cause of today’s move.